Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Baton Rouge, LA
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Bethesda, MD
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Boston, MA
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Grand Rapids, MI
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Rochester, MN
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Chesterfield, MO
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
New York, NY
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Durham, NC
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Cincinnati, OH
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Weatherford, OK
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Weatherford, OK
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Klamath Falls, OR
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Klamath Falls, OR
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Philadelphia, PA
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Knoxville, TN
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Salt Lake City, UT
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Richmond, VA
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
Kennewick, WA
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated:  8/29/2013
GSK Investigational Site
mi
from
La Crosse, WI
Open-Label Extension Study of GSK1605786A
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Status: Enrolling
Updated: 8/29/2013
GSK Investigational Site
mi
from
La Crosse, WI
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Status: Enrolling
Updated:  9/3/2013
DaVita Clinical Research
mi
from
Lakewood, CO
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Status: Enrolling
Updated: 9/3/2013
DaVita Clinical Research
mi
from
Lakewood, CO
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Status: Enrolling
Updated:  9/3/2013
Orlando Clinical Research Center
mi
from
Orlando, FL
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Status: Enrolling
Updated: 9/3/2013
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Status: Enrolling
Updated:  9/3/2013
DaVita Clinical Research
mi
from
Minneapolis, MN
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Status: Enrolling
Updated: 9/3/2013
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor
Evaluation of Closed-loop Titration of the Intravenous Anesthetic Propofol, Sufentanil and Ketamine Guided by BIS Monitor
Status: Enrolling
Updated:  9/10/2013
University Hospital
mi
from
San Antonio, TX
Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor
Evaluation of Closed-loop Titration of the Intravenous Anesthetic Propofol, Sufentanil and Ketamine Guided by BIS Monitor
Status: Enrolling
Updated: 9/10/2013
University Hospital
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study
Status: Enrolling
Updated:  9/11/2013
Atlanta Gastroenterology Associates
mi
from
Atlanta, GA
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study
Status: Enrolling
Updated: 9/11/2013
Atlanta Gastroenterology Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study
Status: Enrolling
Updated:  9/11/2013
Dayton Gastroenterology
mi
from
Beavercreek, OH
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study
Status: Enrolling
Updated: 9/11/2013
Dayton Gastroenterology
mi
from
Beavercreek, OH
Click here to add this to my saved trials
PillCam® Platform With the PillCam Crohn's Disease Capsule
Evaluation of the PillCam® Platform With the PillCam Crohn's Disease Capsule in Visualization of Lesions in the Small Bowel and Colon That May Indicate Crohn's Disease
Status: Enrolling
Updated:  9/11/2013
IU School of Medicine - Gastroenterology
mi
from
Indianapolis, IN
PillCam® Platform With the PillCam Crohn's Disease Capsule
Evaluation of the PillCam® Platform With the PillCam Crohn's Disease Capsule in Visualization of Lesions in the Small Bowel and Colon That May Indicate Crohn's Disease
Status: Enrolling
Updated: 9/11/2013
IU School of Medicine - Gastroenterology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
The University of California Irvine
mi
from
Orange, CA
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
Rush University Medical Center
mi
from
Chicago, IL
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
Indiana University Hospitals
mi
from
Indianapolis, IN
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
Indiana University Hospitals
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
Kendrick Regional Center
mi
from
Indianapolis, IN
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
Kendrick Regional Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
Ochsner Medical Center
mi
from
New Orleans, LA
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
The Mount Sinai Hospital
mi
from
New York, NY
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
The Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
Case Medical Center
mi
from
Cleveland, OH
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated:  9/17/2013
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula
Status: Enrolling
Updated: 9/17/2013
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Huntsville, AL
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Little Rock, AR
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Sacramento, CA
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Omaha, NE
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Dayton, OH
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Kettering, OH
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Simpsonville, SC
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated:  9/20/2013
Clinical Research Facility
mi
from
Richmond, VA
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035 AM2)
A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Status: Enrolling
Updated: 9/20/2013
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair
Multicenter,Prospective, Observational Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair
Status: Enrolling
Updated:  9/23/2013
University of California, Irvine Medical Center
mi
from
Orange, CA
Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair
Multicenter,Prospective, Observational Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair
Status: Enrolling
Updated: 9/23/2013
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Alexandria, LA
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Albuquerque, NM
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Dallas, TX
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated:  9/24/2013
Clinical Research Facility
mi
from
Houston, TX
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Status: Enrolling
Updated: 9/24/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials